지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2016.1
- 수록면
- 255 - 261 (7page)
이용수
초록· 키워드
오류제보하기
Background/Aims: Adalimumab is effective for both remission induction and the maintenance of Crohn’s disease (CD) in Western countries. We evaluated the efficacy of adalimumab in the conventional step-up treatment approach for CD in Korea. Methods: We retrospectively reviewed 62 patients with CD who were treated with adalimumab. Their Crohn’s disease activity index (CDAI) was measured at weeks 4, 8, and 52. Clinical remission was defined as a CDAI score <150. Induction and maintenance outcomes were analyzed.
Results: Forty-one patients (66.1%) achieved a reduction of 70 CDAI points at week 8. Among them, 28 (45.2%) achieved clinical remission at week 8, 20 (32.3%) maintained remission at week 52. The absence of prior anti-tumor necrosis factor (TNF) therapy and Montreal classification L1 at baseline predicted clinical remission at week 8 in the multivariate logistic regression analysis. In the Cox proportional hazards model, the hazard ratio for the secondary loss of response during maintenance therapy after clinical remission induction was significantly higher in patients who showed initial mild CDAI severity or Montreal classification A3. Conclusions: In our study, anti-TNF therapy-naive and Montreal classification L1 were associated with adalimumab efficacy as induction therapy in CD. Further studies are warranted to determine the prognostic factors for the long-term response after adalimumab therapy.
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
이양운 / 2014 / Clinical and Endoscopic Recurrence after Surgical Resection in Patients with Crohn’s Disease / Intestinal research 12(2):117~123
Park SJ / 2014 / Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives / World J Gastroenterol 20:11525~11537
Schnitzler F / 2009 / Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease:results from a single-centre cohort / Gut 58:492~500
Nanda KS / 2013 / Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis / Am J Gastroenterol 108:40~47
Hanauer SB / 2006 / Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease:the CLASSIC-I trial / Gastroenterology 130:323~333
Park SJ / 2014 / Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives / World J Gastroenterol 20:11525~11537
Schnitzler F / 2009 / Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease:results from a single-centre cohort / Gut 58:492~500
Nanda KS / 2013 / Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis / Am J Gastroenterol 108:40~47
Hanauer SB / 2006 / Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease:the CLASSIC-I trial / Gastroenterology 130:323~333
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn’s disease: the Indian experience
Intestinal research
2020 .01
-
Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn’s disease in clinical remission: a pilot study
Intestinal research
2022 .04
-
Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Intestinal research
2023 .01
-
Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
Gut and Liver
2021 .09
-
Clinical Prognostic Score for Predicting Disease Remission with Differentiated Thyroid Cancers
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Therapeutic Efficacy of Oral Enteral Nutrition in Pediatric Crohn’s Disease: A Single Center Non-Comparative Retrospective Study
Yonsei Medical Journal
2016 .01
-
Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
Intestinal research
2021 .10
-
Long-term safety and efficacy of adalimumab for intestinal Behçet’s disease in the open label study following a phase 3 clinical trial
Intestinal research
2017 .01
-
Predictors of Remission in Acute and Continuation Treatment of Depressive Disorders
Clinical Psychopharmacology and Neuroscience
2021 .08
-
An overview of the role of exclusive enteral nutrition for complicated Crohn’s disease
Intestinal research
2019 .01
-
Factors Contributing to Discordance between the 2011 ACR/EULAR Criteria and Physician Clinical Judgment for the Identification of Remission in Patients with Rheumatoid Arthritis
Journal of Korean Medical Science
2016 .01
-
Adalimumab Treatment in Pediatric-Onset Crohn’s Disease Patients after Infliximab Failure: A Single Center Study
Pediatric Gastroenterology, Hepatology & Nutrition
2016 .01
-
Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis
Intestinal research
2018 .01
-
Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience
Intestinal research
2021 .01
-
Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
Intestinal research
2019 .01
-
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Intestinal research
2021 .10
-
Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn’s Disease: A Nationwide, Multicenter Study
Yonsei Medical Journal
2016 .01
-
체계적 문헌고찰 및 메타분석: 크론병 환자에서 Infliximab과 Adalimumab의 유효성 비교
보건의료기술평가
2021 .01
-
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
Intestinal research
2022 .07
-
한약치료를 통해 관해가 유도된 궤양성대장염 환자: 증례보고
Korean Journal of Acupuncture
2019 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0